|
Mutation Information
|
Mutation Site
|
M41L |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
tenofovir (TDF);emtricitabine (FTC);darunavir (DRV);ritonavir;dolutegravir (DTG);elvitegravir (EVG);Cobicistat;abacavir (ABC);lamivudine (LAM) |
|
Country
|
USA |
Literature Information
|
PubMed PMID
|
33941212
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2021 |
|
Journal
|
AIDS research and therapy |
|
Title
|
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV. |
|
Author
|
Rolle CP,Nguyen V,Hinestrosa F,DeJesus E |
|
Evidence
|
The other patient was switched from TDF/FTC/EVG/c to DTG/ABC/3TC (Table (Table2,2, Patient 6) and historical genotypic testing revealed an M184V/I, M41L, T215Y and L74/I which predicted that DTG was the only fully active agent in the study DCR.
|
|
|
HIV Mutation Detail Information